Sarcoidosis
Clinical Snapshot
Sarcoidosis is a multisystem disease of unknown cause defined pathologically by the accumulation of non-caseating (non-necrotizing) granulomas — organized collections of activated macrophages, epithelioid cells, and lymphocytes — in one or more organs.[1] It is best understood as a disorder of exaggerated, dysregulated cell-mediated immunity, most likely triggered by an as-yet-unidentified environmental or occupational antigen (or antigens) in a genetically susceptible host, rather than a single specific disease with one identifiable cause.[1]
Pulmonary-predominant, but genuinely a multisystem disease
The lungs and intrathoracic (hilar and mediastinal) lymph nodes are involved in roughly 90% of patients and dominate the diagnostic and staging discussion in this chapter, but sarcoidosis can involve essentially any organ — and which organs are involved, far more than the radiographic stage alone, is what actually determines how aggressively to treat.[2]
Why organ involvement matters more than "how much disease"
A patient with extensive Stage II pulmonary infiltrates who is asymptomatic may need nothing more than observation, while a patient with a single, small, but arrhythmogenic focus of cardiac granulomatous inflammation needs urgent, aggressive treatment. This chapter is organized around that principle throughout Choose Initial Treatment and Special Populations.
Cardiac sarcoidosis
Clinically apparent in only a minority of patients overall, but a genuinely important minority: granulomatous cardiac involvement can cause conduction block, ventricular arrhythmia, and sudden cardiac death, and can be the first and only presenting manifestation of the disease. Subclinical granulomatous cardiac involvement is found far more often than clinically apparent disease when actively looked for with advanced cardiac imaging.[3][4] See Special Populations and Red Flags & Refer.
Neurosarcoidosis
Affects roughly 5-10% of patients with sarcoidosis and can precede, accompany, or occasionally occur without any other recognized organ involvement; cranial neuropathy — especially facial nerve palsy — is the single most common presentation.[5] See Special Populations.
Ocular sarcoidosis
Uveitis (anterior, posterior, or panuveitis) is common and can threaten vision; it is frequently silent until damage is already underway, which is why a baseline ophthalmologic examination is recommended for every patient at diagnosis, not only those with eye symptoms.[2] See Special Populations and Monitoring & Follow-Up.
Cutaneous sarcoidosis
Affects roughly a quarter of patients; erythema nodosum (a nonspecific, reactive, good-prognosis finding) and lupus pernio (a specific, disfiguring, chronic sarcoid skin lesion associated with more refractory disease) look and behave very differently and carry opposite prognostic implications — see Recognize the Condition and Special Populations.
Hypercalcemia
A genuinely important, distinctly sarcoidosis-specific metabolic complication driven by granuloma-derived extrarenal activation of vitamin D, with direct and specific implications for vitamin D and calcium supplementation in this population — see Non-Pharmacologic Treatment, Choose Initial Treatment, and Special Populations.
Epidemiology
In Ontario, a population-based cohort study using health administrative data from 1996 to 2015 found the prevalence of sarcoidosis rose to 143 per 100,000 population by 2015 — a 116% increase from 1996 — with age- and sex-adjusted mortality also rising over the same period, from 1.15% to 1.47%.[6] Internationally, incidence and prevalence vary substantially by ethnicity: sarcoidosis is roughly three times more common, and tends to run a more severe, more chronic course, in Black populations compared with White populations, and is also disproportionately common in Scandinavian populations.[6] Most patients are diagnosed between ages 20 and 40, with a second, smaller peak in women older than 50.
Recognize the Condition
Löfgren syndrome — an acute presentation with a genuinely good prognosis
Löfgren syndrome is an acute triad of bilateral hilar lymphadenopathy, erythema nodosum, and periarticular ankle involvement (arthralgia or true arthritis, often with fever) — a distinctive presentation worth recognizing precisely because it changes management: it is self-limited in roughly 80-90% of patients, and biopsy confirmation is often unnecessary when the clinical picture is this classic.[1] Prognosis tracks HLA-DRB1 genotype closely: up to about 95% of HLA-DRB1*03-positive patients have resolving disease within 2 years, compared with about 51% of HLA-DRB1*03-negative patients.[7] See Choose Initial Treatment for the watchful-waiting approach this good prognosis supports.
Heerfordt syndrome — a second acute, good-prognosis variant
Also called uveoparotid fever: parotid gland enlargement, anterior uveitis, facial nerve palsy, and fever occurring together. Like Löfgren syndrome, it is a distinctive acute presentation that, once recognized, typically does not require an extensive additional diagnostic work-up.
Pulmonary symptoms
Dry cough, exertional dyspnea, and vague chest discomfort or tightness are the most common respiratory complaints, developing gradually over weeks to months; wheeze can occur with endobronchial granulomatous involvement.[2]
Constitutional symptoms
Fatigue — often disproportionate to the degree of organ involvement found on investigation — along with low-grade fever, night sweats, and unintentional weight loss are common and can precede a specific organ diagnosis by months.
Cutaneous findings
- Erythema nodosum — tender, erythematous, subcutaneous nodules typically over the anterior shins; nonspecific for sarcoidosis (also seen with infections, other inflammatory diseases, and some medications) but, in the context of Löfgren syndrome, a genuinely reassuring, good-prognosis finding.
- Lupus pernio — violaceous-to-red, indurated plaques and nodules, characteristically on the nose, cheeks, ears, and fingers; unlike erythema nodosum, this is a specific sarcoid skin lesion (not merely reactive), it is disfiguring, and it is strongly associated with chronic, fibrotic, more treatment-refractory disease, including upper respiratory tract and pulmonary fibrotic involvement — a genuinely different prognosis from erythema nodosum despite both being "skin findings."
- Subcutaneous nodules, maculopapular eruptions, and granulomatous infiltration of old scars or tattoos are also recognized cutaneous presentations.
Ocular findings
Anterior uveitis presents with eye redness, pain, and photophobia; posterior uveitis or panuveitis is more likely to present with floaters or blurred/reduced vision and is more likely to threaten sight. Dry eye from lacrimal gland infiltration is also common. Because ocular sarcoidosis can be genuinely silent even when vision-threatening, absence of eye symptoms does not exclude it — see Monitoring & Follow-Up.
Cardiac findings
Palpitations, presyncope, syncope, and symptoms of heart failure can all be presenting features — but cardiac sarcoidosis can also be entirely asymptomatic until a heart block or a sustained ventricular arrhythmia presents as sudden cardiac death, which is exactly why systematic screening (not just symptom-triggered testing) is built into Assessment & Diagnosis and Monitoring & Follow-Up for every patient, not only those with cardiac symptoms.[3]
Neurologic findings
Cranial neuropathy — most often unilateral or bilateral facial nerve (CN VII) palsy — is the single most common neurosarcoidosis presentation.[5] Other patterns include an aseptic-meningitis-like picture (headache, meningismus), myelopathy, peripheral or small-fiber neuropathy, and, less commonly, hypothalamic-pituitary involvement (diabetes insipidus and other endocrinopathies) or mass-like intracranial granulomatous lesions.[5]
Hypercalcemia-related symptoms
Polyuria and polydipsia, constipation, nephrolithiasis (sometimes the presenting complaint), and, in more severe cases, confusion are the clinical clues; because the mechanism is granuloma-driven, symptoms can appear or worsen specifically after increased sun exposure or vitamin D intake — see Special Populations.
Risk Factors
Demographic risk factors
- Age — most patients are diagnosed between 20 and 40 years old, with a second, smaller peak in women older than 50.
- Race and ethnicity — incidence and prevalence are substantially higher, and the clinical course tends to be more chronic and severe, in Black populations compared with White populations; Scandinavian populations also have disproportionately high incidence.[6]
- Sex — sarcoidosis affects both sexes, with a somewhat higher overall prevalence in women, particularly around the second, later-life peak.
Genetic risk factors
HLA class II alleles are the most consistently replicated genetic association. HLA-DRB1*03 is strongly associated with the Löfgren syndrome phenotype and predicts a favourable, self-limited disease course, while HLA-DRB1*15 is a risk factor for chronic, nonresolving disease.[7] A first-degree relative with sarcoidosis modestly increases risk, consistent with a genuine genetic contribution layered on top of an environmental trigger.
Environmental and occupational risk factors
No single causative antigen has been identified, but epidemiologic studies have linked sarcoidosis risk to specific environmental and occupational exposures, including insecticide/pesticide exposure, mold or mildew exposure, and certain occupational dust exposures — reinforcing that sarcoidosis, like hypersensitivity pneumonitis (see the Interstitial Lung Disease chapter), likely represents an exaggerated immune response to an inhaled antigen or antigens rather than a single specific cause.[1]
Red Flags & Refer
Any of the following changes the plan from routine chronic disease management to urgent, often same-day, escalation:
- New palpitations, presyncope, syncope, or a new conduction abnormality on ECG in a patient with known or suspected sarcoidosis — this needs urgent cardiology evaluation for cardiac sarcoidosis, given the real risk of high-grade heart block and sudden cardiac death from ventricular arrhythmia (see Special Populations). Do not attribute new cardiac symptoms in a sarcoidosis patient to anxiety or deconditioning without first excluding cardiac sarcoidosis.
- New cranial neuropathy (especially a new facial droop), headache with meningismus, myelopathy, or another new focal neurologic deficit — urgent neurology referral for suspected neurosarcoidosis (see Special Populations).
- Acute vision loss, a painful red eye, or significant new photophobia — same-day or next-day ophthalmology referral; posterior uveitis and panuveitis can threaten vision quickly and are not "watch and wait" findings.
- Symptomatic or severe hypercalcemia (confusion, marked dehydration, acute kidney injury) — urgent medical evaluation; see Choose Initial Treatment and Special Populations for the corticosteroid-centred management approach.
- Rapid pulmonary function decline or new respiratory failure — urgent respirology assessment rather than waiting for the next scheduled visit.
- Any diagnostic uncertainty about tuberculosis or another granulomatous infection — do not start corticosteroids or other immunosuppression for presumed sarcoidosis until active infection, especially tuberculosis, has been genuinely excluded (see Assessment & Diagnosis and Common Errors to Avoid); treating undiagnosed TB with corticosteroids can cause disseminated, life-threatening infection.
Assessment & Diagnosis
Three diagnostic pillars
The current ATS clinical practice guideline frames the diagnosis of sarcoidosis around three elements that must all be satisfied: (1) a compatible clinical and radiographic presentation, (2) finding non-necrotizing (non-caseating) granulomatous inflammation in one or more tissue samples, and (3) exclusion of other diseases capable of producing a similar clinical and/or histologic picture.[2] No single test is diagnostic on its own — sarcoidosis remains, genuinely, a diagnosis of compatible findings plus exclusion, not a positive test result.
Tuberculosis and other mycobacterial or fungal granulomatous infections are the most important mimics to exclude, because the consequence of getting this wrong is not neutral: corticosteroids and other immunosuppressive agents used to treat sarcoidosis can cause unrecognized tuberculosis to disseminate, with genuinely serious and sometimes fatal consequences.[2] A thorough TB risk assessment — travel/residence in or exposure from a TB-endemic country, known TB contact, immunocompromise, and compatible imaging features — together with tuberculin skin testing or an interferon-gamma release assay, and acid-fast bacilli smear/culture of biopsy tissue when infection is even moderately plausible, should be completed and reviewed before committing a patient to significant corticosteroid therapy.[2] This is not a formality — it is the single most consequential exclusion in the entire diagnostic pathway (see Common Errors to Avoid).
Biopsy — site selection favours the least invasive accessible option
When tissue confirmation is needed, choose the safest, most accessible site with reasonable diagnostic yield first — a skin lesion, a peripheral or conjunctival nodule, an enlarged peripheral lymph node, or minor salivary gland tissue — before moving to more invasive intrathoracic sampling.[2] For intrathoracic disease, endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) of mediastinal/hilar lymph nodes is preferred over mediastinoscopy given comparable diagnostic yield with meaningfully lower procedural risk.[2] Biopsy can reasonably be omitted in a patient with a sufficiently classic presentation of Löfgren syndrome (see Recognize the Condition), where the diagnosis is clinical.
Radiographic (Scadding) staging
Chest radiograph staging remains a simple, widely used prognostic framework, even though it is purely descriptive and does not itself establish the diagnosis:
| Stage | Radiographic finding | Approximate spontaneous remission rate |
|---|---|---|
| Stage 0 | Normal chest radiograph (extrathoracic disease only) | Not applicable |
| Stage I | Bilateral hilar lymphadenopathy alone, clear lung fields | ~60-90% |
| Stage II | Bilateral hilar lymphadenopathy plus pulmonary infiltrates | ~40-70% |
| Stage III | Pulmonary infiltrates without hilar lymphadenopathy | ~10-20% |
| Stage IV | Pulmonary fibrosis (honeycombing, volume loss, architectural distortion) | Does not occur |
Most spontaneous remissions, regardless of initial stage, occur within the first 2 years after presentation, and the likelihood of remission falls once disease has persisted beyond about 5 years — a genuinely important expectation-setting point for watchful waiting (see Treatment Targets and Choose Initial Treatment).
Baseline testing recommended for every newly diagnosed patient
- Serum calcium — a strong recommendation in the ATS guideline, given the genuine and specific risk of granuloma-driven hypercalcemia in this population (see Special Populations).[2]
- ECG — recommended for every patient at diagnosis, not only those with cardiac symptoms, since cardiac sarcoidosis can be clinically silent (see Special Populations and Monitoring & Follow-Up).[3]
- Baseline ophthalmologic examination — recommended for every patient, again because ocular sarcoidosis can be silent (see Special Populations and Monitoring & Follow-Up).
- CBC, renal function, and liver function tests as part of the general work-up and as a pre-treatment baseline.
- Pulmonary function testing (spirometry and DLCO) to characterize baseline pulmonary status.
Differential diagnosis
Beyond tuberculosis and other mycobacterial/fungal granulomatous infections, consider lymphoma (especially with asymmetric or bulky lymphadenopathy), berylliosis (a granulomatous lung disease clinically and radiographically similar to sarcoidosis, caused by occupational beryllium exposure — aerospace, electronics, and metal-alloy work are classic exposures, and a targeted occupational history is the only way to catch it), and hypersensitivity pneumonitis (see the Interstitial Lung Disease chapter).
Treatment Targets
Sarcoidosis has no cure, and a substantial proportion of patients — particularly those with Löfgren syndrome or Stage I disease — will remit spontaneously without any treatment at all (see Assessment & Diagnosis). The treatment goal is therefore not to "clear granulomas" or normalize imaging in every patient, but to:
- Prevent or reverse organ dysfunction in organs where ongoing granulomatous inflammation causes genuine, irreversible harm if untreated — this is the central decision driver, not the radiographic stage or extent of disease (see Choose Initial Treatment).
- Treat high-risk organ involvement aggressively regardless of symptom severity — cardiac, neurologic, and posterior/panuveitic ocular disease carry disproportionate morbidity and mortality risk and change the treatment threshold even when the patient feels reasonably well (see Special Populations).
- Control troublesome symptoms — cough, dyspnea, fatigue, arthralgia — that meaningfully affect quality of life, even when the organ involved is not itself at risk of lasting damage.
- Minimize cumulative corticosteroid toxicity over what is often a multi-year treatment course, by using the lowest effective dose, tapering deliberately, and introducing a steroid-sparing agent proactively rather than only after toxicity has already appeared (see Choose Initial Treatment).
- Support watchful waiting as a genuine, appropriate default for asymptomatic disease without high-risk organ involvement — treatment is not automatically "better" than observation when the disease itself is likely to remit (see Choose Initial Treatment).
Choose Initial Treatment
Asymptomatic patients with Stage I disease and no high-risk organ involvement have such a high rate of spontaneous remission (see Assessment & Diagnosis) that observation alone, with scheduled follow-up, is the guideline-consistent default rather than a compromise.[1] For Löfgren syndrome specifically, treat the acute symptoms — NSAIDs for fever and periarticular arthralgia/arthritis — and reserve a short corticosteroid course for genuinely severe, function-limiting symptoms rather than starting it reflexively; the syndrome itself resolves in roughly 80-90% of patients, more reliably in HLA-DRB1*03-positive patients (see Recognize the Condition).[7]
When to start: symptomatic pulmonary disease with functional impairment, radiographically progressive disease, or any organ involvement causing dysfunction — this is the general indication threshold across the ERS treatment guideline's organ-specific recommendations.[8]
Typical starting dose: prednisone 20 mg PO once daily is a reasonable, evidence-supported starting point per the ERS guideline for uncomplicated symptomatic pulmonary disease, though many clinicians and some protocols use 20-40 mg/day depending on disease severity.[8] Reassess response at 4-6 weeks.
Tapering: once a good, sustained response is achieved, taper gradually — for example, stepping down through 10 mg, 5 mg, and 2.5 mg daily doses over roughly 3-4 weeks per step — to complete a minimum total treatment duration of about 6 months; tapering too quickly is one of the most common reasons for relapse.[8]
Duration and toxicity: many patients need corticosteroid therapy for a year or longer, and some need it indefinitely at a low maintenance dose; this genuinely significant duration of exposure is exactly why proactively planning bone-health monitoring (Monitoring & Follow-Up), glucose monitoring, and — for disease expected to need more than roughly 3 months of meaningful-dose corticosteroids, or that relapses on tapering — early introduction of a steroid-sparing agent below is standard practice, not a last resort.
Cardiac, neurologic, and posterior-segment/panuveitic ocular sarcoidosis are managed differently from "routine" pulmonary or cutaneous disease specifically because the consequences of undertreating them are severe and sometimes irreversible — sudden cardiac death, permanent neurologic deficit, vision loss.[3][5] In practice this generally means a higher initial corticosteroid dose (commonly in the range of 0.5-1 mg/kg/day prednisone equivalent, or higher for active myocardial or CNS inflammation), a lower threshold to add a steroid-sparing agent early rather than waiting for a corticosteroid taper to fail, and urgent co-management with the relevant specialist (cardiology, neurology, ophthalmology) from the outset rather than a delayed referral once first-line treatment has already been tried.[8] See Special Populations for organ-specific detail.
Methotrexate is the best-studied and generally preferred first steroid-sparing agent, typically dosed at 10-15 mg PO (or subcutaneous) once weekly with folic acid supplementation, used for pulmonary, cutaneous, cardiac, and neurologic sarcoidosis.[8] Onset of steroid-sparing benefit is gradual — typically 8-12 weeks — so it is started proactively, in anticipation of a prolonged corticosteroid course, rather than only once corticosteroid toxicity has already appeared. Baseline and periodic CBC and liver function monitoring are required (see Monitoring & Follow-Up); avoid in significant renal impairment and in pregnancy.
Azathioprine (typically 2-3 mg/kg/day) is a reasonable alternative when methotrexate is contraindicated or not tolerated — particularly with renal impairment, since methotrexate is renally cleared — with its own CBC/liver monitoring requirements and a clinically important interaction with allopurinol.[8]
Mycophenolate mofetil is a further alternative, used particularly for neurosarcoidosis, where it and azathioprine are both reasonable second-line choices alongside methotrexate.[8]
Infliximab (an anti-TNF-alpha monoclonal antibody) is the best-evidenced biologic for sarcoidosis refractory to corticosteroids and a first steroid-sparing agent, including chronic pulmonary disease, cutaneous disease (particularly lupus pernio), cardiac sarcoidosis, and neurosarcoidosis.[9][8] Dosing used in the pivotal trial and in subsequent clinical use is 3-5 mg/kg IV at weeks 0, 2, and 6, then every 4-8 weeks for maintenance.[9] Screen for latent tuberculosis and hepatitis B before starting — the same infection-exclusion imperative from Assessment & Diagnosis applies with particular force before anti-TNF therapy, which carries its own recognized risk of reactivating latent TB.[2] Adalimumab is a reasonable alternative anti-TNF agent, with a more limited evidence base specifically in sarcoidosis.
Despite also being an anti-TNF-alpha agent, etanercept has not shown efficacy for sarcoidosis in clinical trials and has, paradoxically, been reported to induce or unmask granulomatous disease in some patients treated with it for other indications — it should not be substituted for infliximab or adalimumab under the assumption that all anti-TNF agents are interchangeable for this disease.[8]
Corticosteroids suppress the extrarenal 1-alpha-hydroxylase activity in activated macrophages that drives sarcoidosis-associated hypercalcemia and are the treatment of choice for it, generally at doses similar to those used for other organ-threatening disease.[2] Hydroxychloroquine is a genuinely useful steroid-sparing option specifically for hypercalcemia and for cutaneous disease, since it also reduces macrophage 1,25-dihydroxyvitamin D production.[8] For acute, more severe hypercalcemia: prioritize volume repletion with isotonic saline first; if a diuretic is needed after volume repletion, use a loop diuretic (e.g., furosemide) — never a thiazide, which reduces renal calcium excretion and will worsen hypercalcemia rather than treat it. See Non-Pharmacologic Treatment and Special Populations for the vitamin D/calcium supplementation caution that follows directly from this mechanism.
Non-Pharmacologic Treatment
Vitamin D and calcium — a genuinely important caution specific to this population
Because activated macrophages in sarcoidosis granulomas can convert vitamin D to its active form independent of the kidney's normal feedback regulation, standard population-level vitamin D and calcium supplementation advice does not apply unmodified to patients with sarcoidosis.[2] Before recommending or continuing vitamin D or calcium supplementation — including routine bone-health supplementation started for corticosteroid-associated osteoporosis prevention — check a recent serum calcium (and, where available, 1,25-dihydroxyvitamin D) rather than assuming standard-dose supplementation is automatically safe. This does not mean vitamin D is always contraindicated in sarcoidosis; it means it needs monitoring in this population that it would not need in most other patients.
Sun exposure
Because cutaneous vitamin D synthesis feeds the same mechanism, advise patients with a history of hypercalcemia to avoid prolonged, unprotected sun exposure and to mention any planned major increase in outdoor time (for example, a sunny vacation) at a follow-up visit.
Bone health during long-term corticosteroid therapy
Given how often sarcoidosis treatment runs for a year or longer (see Choose Initial Treatment), plan proactively for corticosteroid-related bone loss — but coordinate calcium/vitamin D supplementation decisions specifically with the hypercalcemia caution above rather than applying a standard osteoporosis-prevention protocol unmodified.
Infection screening and vaccination before immunosuppression
Complete tuberculosis and hepatitis B screening before starting a steroid-sparing agent or, especially, a biologic (see Choose Initial Treatment); bring routine immunizations up to date beforehand, and avoid live vaccines once a patient is on a significantly immunosuppressive regimen.
Smoking cessation and general lifestyle
Counsel every current smoker to quit. Regular physical activity and, for patients with more advanced pulmonary involvement, pulmonary rehabilitation can meaningfully improve the fatigue and reduced exercise tolerance that are common even in patients without severe lung function impairment.
Patient education and psychosocial support
Fatigue is one of the most burdensome and most underrecognized symptoms of sarcoidosis, often present independent of measurable organ dysfunction, and deserves acknowledgment and support rather than being dismissed once "the scan looks fine." Direct patients toward reliable, disease-specific resources such as the Foundation for Sarcoidosis Research and the Canadian Lung Association (lung.ca) rather than unfiltered internet searches.
Special Populations
Cardiac sarcoidosis
Screen with a 12-lead ECG in every patient with sarcoidosis at diagnosis, regardless of cardiac symptoms, since clinically silent conduction and rhythm abnormalities are common.[3] A new abnormality on screening ECG, or any cardiac symptom (see Red Flags & Refer), should prompt further evaluation — echocardiography, ambulatory rhythm monitoring, and advanced imaging (cardiac MRI with late gadolinium enhancement, or FDG-PET) as guided by the specific finding and local availability, per the 2024 AHA scientific statement.[4]
Immunosuppression is the primary treatment for active cardiac inflammation, generally with higher-dose corticosteroids than for uncomplicated pulmonary disease and a lower threshold to add a steroid-sparing agent (see Choose Initial Treatment); infliximab has a genuine, reported role for cardiac sarcoidosis refractory to corticosteroids and a first-line steroid-sparing agent.[4]
Device therapy is guided by risk stratification, not by immunosuppression status alone — the two are complementary, not substitutes for one another. ICD implantation carries a Class I (strongest) recommendation for a history of cardiac arrest or sustained ventricular arrhythmia, and for a left ventricular ejection fraction of 35% or less; a Class IIa recommendation applies to inducible ventricular arrhythmia on electrophysiology study, a planned permanent pacemaker, and syncope or near-syncope believed to have an arrhythmic origin; a weaker Class IIb recommendation applies to mild-to-moderate LV systolic dysfunction (ejection fraction 36-49%) and/or right ventricular systolic dysfunction.[3][4] Antiarrhythmic therapy and catheter ablation both have a role for recurrent ventricular arrhythmia despite device therapy and adequate immunosuppression.
Neurosarcoidosis
The Neurosarcoidosis Consortium Consensus Group's 2018 criteria classify neurosarcoidosis as definite, probable, or possible, based on a combination of compatible clinical presentation, supportive neuroimaging or other neurodiagnostic testing, exclusion of alternative diagnoses, and — for a definite diagnosis — pathologic confirmation from either the nervous system itself or another organ combined with a fully compatible neurologic syndrome.[5] Cranial neuropathy, especially facial nerve palsy, is the most common presentation; MRI of the brain and spine with contrast is the key imaging investigation, and cerebrospinal fluid findings are typically nonspecific (mildly elevated protein, lymphocytic pleocytosis) rather than diagnostic on their own.[5] Because neurosarcoidosis carries a genuine relapse risk and can cause permanent neurologic deficit if undertreated, it is generally managed with a higher initial corticosteroid dose and longer duration than uncomplicated pulmonary disease, with earlier introduction of a steroid-sparing agent (methotrexate, azathioprine, or mycophenolate mofetil) rather than waiting for a corticosteroid taper to fail (see Choose Initial Treatment).[8]
Ocular sarcoidosis
Anterior uveitis is managed acutely with the general principles covered in the Anterior Uveitis chapter (topical corticosteroids and cycloplegia as first-line, urgent ophthalmology involvement); posterior uveitis and panuveitis are more likely to be vision-threatening and generally require systemic corticosteroid or steroid-sparing therapy in addition to, or instead of, topical treatment, coordinated with ophthalmology.[2] Because ocular sarcoidosis can be entirely silent, every patient should have a baseline ophthalmologic examination at diagnosis regardless of symptoms, with periodic reassessment thereafter (see Monitoring & Follow-Up).
Cutaneous sarcoidosis
Erythema nodosum requires no specific treatment beyond symptomatic care (NSAIDs, leg elevation) and resolves with the underlying disease (see Choose Initial Treatment's Löfgren syndrome discussion). Lupus pernio and other specific cutaneous sarcoid lesions are a different story: limited disease can be managed with topical or intralesional corticosteroids, but extensive or disfiguring lupus pernio — which is itself a marker of chronic, more fibrotic, more treatment-refractory disease — typically needs systemic therapy, with hydroxychloroquine, methotrexate, and infliximab (which has a particularly well-reported track record specifically for lupus pernio) all reasonable options depending on severity.[8]
Hypercalcemia and renal involvement
Beyond the acute management in Choose Initial Treatment, ongoing hypercalcemia and hypercalciuria increase the risk of nephrolithiasis and nephrocalcinosis, and can, over time, contribute to chronic kidney disease — reasons to monitor serum and, where feasible, 24-hour urine calcium periodically in any patient with a history of hypercalcemia (see Monitoring & Follow-Up), and to revisit the vitamin D/calcium supplementation caution (see Non-Pharmacologic Treatment) at every relevant visit rather than only at diagnosis.
Pregnancy
Sarcoidosis often improves during pregnancy, plausibly related to physiologic changes in maternal immune tolerance and endogenous corticosteroid production, with a recognized risk of flare in the postpartum period. Prednisone is the preferred agent if treatment is needed during pregnancy. Methotrexate and mycophenolate mofetil are both teratogenic and contraindicated; azathioprine is generally considered the better-tolerated immunosuppressive option in pregnancy when a steroid-sparing agent is genuinely needed, though the decision should be individualized with obstetric and specialist input.
Monitoring & Follow-Up
- Routine follow-up every 3-6 months for most patients, more frequently around diagnosis, during a corticosteroid taper, or for actively progressing/high-risk organ disease.
- Pulmonary function testing (spirometry, DLCO) and chest imaging periodically to track pulmonary disease trajectory, with frequency individualized to severity and stability.
- Serum calcium at diagnosis and periodically thereafter, more frequently during any period of increased sun exposure, vitamin D intake, or immobilization, and always before initiating or increasing vitamin D/calcium supplementation (see Non-Pharmacologic Treatment).[2]
- Baseline ECG for every patient at diagnosis and periodically thereafter, with a low threshold to repeat or escalate to advanced cardiac imaging for any new cardiac symptom (see Special Populations).[3]
- Baseline ophthalmologic examination for every patient at diagnosis, with periodic reassessment (commonly annually, more often if abnormal or symptomatic), given how often ocular sarcoidosis is clinically silent.
- Methotrexate/azathioprine: baseline CBC, renal function, and liver function tests, then periodically (for example, every 4-8 weeks initially, spacing out once stable) for the duration of therapy.
- Infliximab: confirm negative TB/hepatitis B screening before starting (see Choose Initial Treatment), and monitor clinically for infusion reactions and infection at each visit.
- Hydroxychloroquine: baseline and periodic ophthalmologic monitoring specifically for retinal toxicity — a distinct surveillance requirement from the ocular sarcoidosis monitoring above.
- Bone density assessment for patients on a prolonged corticosteroid course, coordinated with the vitamin D/calcium caution specific to this population (see Non-Pharmacologic Treatment).
- Screen for adrenal insufficiency symptoms when tapering corticosteroids after a prolonged course, and taper gradually rather than stopping abruptly.
Common Errors to Avoid
- Starting corticosteroids for presumed sarcoidosis before genuinely excluding tuberculosis and other granulomatous infections — this is the single most consequential error in the entire chapter (see Assessment & Diagnosis and Red Flags & Refer).[2]
- Treating radiographic stage or extent of disease alone, in an asymptomatic patient with no high-risk organ involvement, rather than basing the treatment decision on actual organ dysfunction and risk (see Treatment Targets).
- Recommending routine, unmonitored vitamin D and/or calcium supplementation to a patient with sarcoidosis — including for standard corticosteroid-associated bone-health prevention — without first checking serum calcium (see Non-Pharmacologic Treatment and Special Populations).[2]
- Using a thiazide diuretic for a sarcoidosis patient with hypercalcemia — thiazides reduce renal calcium excretion and will worsen, not treat, hypercalcemia; use a loop diuretic instead, and only after volume repletion (see Choose Initial Treatment).
- Assuming a sarcoidosis patient without cardiac symptoms does not have cardiac involvement — clinically silent cardiac sarcoidosis is common and can present first as sudden cardiac death; a baseline ECG is recommended for every patient regardless of symptoms (see Assessment & Diagnosis and Special Populations).[3]
- Skipping the baseline ophthalmologic examination in an asymptomatic patient — ocular sarcoidosis, like cardiac sarcoidosis, can be clinically silent until vision is already threatened.
- Substituting etanercept for infliximab or adalimumab under the assumption that all anti-TNF agents work equally well for sarcoidosis — etanercept has not shown efficacy and has been reported to induce granulomatous disease (see Choose Initial Treatment).[8]
- Stopping a prolonged corticosteroid course abruptly rather than tapering — both disease relapse and adrenal insufficiency are real risks.
- Starting infliximab or another biologic without first completing TB and hepatitis B screening (see Choose Initial Treatment and Monitoring & Follow-Up).
- Misclassifying erythema nodosum and lupus pernio as interchangeable "sarcoid rashes" — they carry essentially opposite prognostic implications and need different management (see Recognize the Condition and Special Populations).
Clinical Decision Algorithm
Drug Tables
Systemic Corticosteroids
First-line therapy for symptomatic, progressive, or organ-threatening sarcoidosis. See Choose Initial Treatment for organ-specific dosing intensity and tapering detail.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Prednisone | 20 mg PO once daily as a reasonable starting dose for uncomplicated symptomatic pulmonary disease; 0.5-1 mg/kg/day or higher for cardiac, neurologic, or other high-risk organ involvement; taper over a minimum of 6 months once response is established | Hyperglycemia, osteoporosis, adrenal suppression, weight gain, mood/sleep disturbance, increased infection risk, hypertension, cataracts, avascular necrosis with prolonged high-dose use | Additive risk of GI bleeding with NSAIDs; reduced vaccine response; monitor glucose closely in diabetes | Check serum calcium before assuming vitamin D/calcium supplementation is safe in this population (see Non-Pharmacologic Treatment); taper deliberately, never abruptly, given the real risk of both relapse and adrenal insufficiency. |
Steroid-Sparing Antimetabolites
Introduced proactively for disease expected to need a prolonged corticosteroid course, or for relapse on tapering — not only after corticosteroid toxicity has already appeared.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Methotrexate | 10-15 mg PO or SC once weekly, with folic acid supplementation | Hepatotoxicity, myelosuppression, GI upset, stomatitis, rare methotrexate-induced pneumonitis | Reduced clearance/increased toxicity with NSAIDs and trimethoprim-sulfamethoxazole; avoid alcohol | Preferred first steroid-sparing agent for pulmonary, cutaneous, cardiac, and neurologic disease; gradual onset of benefit (8-12 weeks); contraindicated in pregnancy; avoid in significant renal impairment. |
| Azathioprine | 2-3 mg/kg/day PO | Myelosuppression, hepatotoxicity, increased infection risk, GI upset, rare pancreatitis | Markedly increased toxicity with concomitant allopurinol; interacts with TPMT metabolism | Reasonable alternative when methotrexate is contraindicated or not tolerated, particularly with renal impairment. |
| Mycophenolate mofetil | Individualized, typically titrated toward 1-1.5 g PO twice daily as tolerated | GI upset, myelosuppression, increased infection risk | Reduced absorption with concomitant antacids/proton pump inhibitors; additive myelosuppression with other immunosuppressants | Used particularly for neurosarcoidosis alongside methotrexate and azathioprine as second-line options; teratogenic — requires reliable contraception. |
Biologic Therapy — Anti-TNF Agents
For disease refractory to corticosteroids and a first-line steroid-sparing agent. Confirm latent TB and hepatitis B screening before starting either agent below (see Assessment & Diagnosis and Choose Initial Treatment).
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Infliximab | 3-5 mg/kg IV at weeks 0, 2, and 6, then every 4-8 weeks for maintenance | Infusion reactions, increased infection risk including TB reactivation, rare drug-induced lupus-like syndrome, rare demyelinating disease | Increased infection risk with concomitant immunosuppressants; live vaccines contraindicated during treatment | Best-evidenced biologic for sarcoidosis; particularly well-reported for lupus pernio, cardiac sarcoidosis, and neurosarcoidosis refractory to first-line steroid-sparing therapy. |
| Etanercept | Not applicable — not recommended for sarcoidosis | No demonstrated efficacy in sarcoidosis; reported to induce or unmask granulomatous disease in some patients treated with it for other indications | Not applicable | Do not substitute for infliximab or adalimumab under the assumption that all anti-TNF agents are interchangeable for this disease. |
Antimalarial — Hypercalcemia and Cutaneous Disease
A steroid-sparing option specifically useful where its mechanism — reducing macrophage 1,25-dihydroxyvitamin D production — directly addresses the problem.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Hydroxychloroquine | 200-400 mg PO daily (weight-based, per current dosing recommendations) | Retinal toxicity with long-term use, GI upset, rare cardiomyopathy/QT prolongation, skin pigmentation changes | Additive QT-prolonging effect with other QT-prolonging drugs | Particularly useful for hypercalcemia and cutaneous sarcoidosis, including lupus pernio; requires its own baseline and periodic ophthalmologic monitoring for retinal toxicity, distinct from the ocular sarcoidosis monitoring already in place for many patients. |
References
- Statement on Sarcoidosis — Joint Statement of the American Thoracic Society (ATS), European Respiratory Society (ERS), and World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG). Am J Respir Crit Care Med 1999;160(2):736-755
- Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline — American Thoracic Society (Crouser ED, Maier LA, Wilson KC, Bonham CA, Morgenthau AS, Patterson KC, et al.). Am J Respir Crit Care Med 2020;201(8):e26-e51
- HRS Expert Consensus Statement on the Diagnosis and Management of Arrhythmias Associated With Cardiac Sarcoidosis — Heart Rhythm Society (Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS, et al.). Heart Rhythm 2014;11(7):1305-1323
- Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association — American Heart Association (Cheng RK, Kittleson MM, Beavers CJ, Birnie DH, Blankstein R, Bravo PE, Gilotra NA, Judson MA, Patton KK, Rose-Bovino L). Circulation 2024;149(21):e1197-e1216
- Definition and Consensus Diagnostic Criteria for Neurosarcoidosis: From the Neurosarcoidosis Consortium Consensus Group — JAMA Neurology (Stern BJ, Royal W 3rd, Gelfand JM, Clifford DB, Tavee J, Pawate S, et al.). JAMA Neurol 2018;75(12):1546-1553
- Epidemiology and health outcomes of sarcoidosis in a universal healthcare population: a cohort study — European Respiratory Journal — Ontario, Canada cohort (Fidler LM, Balter M, Fisher JH, To T). Eur Respir J 2019;54(4):1900444
- Löfgren's Syndrome: Human Leukocyte Antigen Strongly Influences the Disease Course — American Journal of Respiratory and Critical Care Medicine (Grunewald J, Eklund A). Am J Respir Crit Care Med 2009;179(4):307-312
- ERS clinical practice guidelines on treatment of sarcoidosis — European Respiratory Society (Baughman RP, Valeyre D, Korsten P, Mathioudakis AG, Wuyts WA, Wells A, et al.). Eur Respir J 2021;58(6):2004079
- Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement — American Thoracic Society (Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U, du Bois R, et al.). Am J Respir Crit Care Med 2006;174(7):795-802
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.